WallStreetZenWallStreetZen

NASDAQ: MTEM
Molecular Templates Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

MTEM past earnings growth

How has MTEM's earnings growth performed historically?
Company
-92.71%
Industry
52.08%
Market
61.16%
MTEM's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
MTEM's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

MTEM past revenue growth

How has MTEM's revenue growth performed historically?
Company
190.1%
Industry
148.4%
Market
16.96%
MTEM's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
MTEM's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
MTEM's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

MTEM earnings and revenue history

Current Revenue
$57.3M
Current Earnings
-$8.1M
Current Profit Margin
-14.2%

MTEM Return on Equity

Current Company
-7,646.1%
Current Industry
-63.5%
Current Market
188%
MTEM's Return on Equity (-7,646.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when MTEM announces earnings.

MTEM Return on Assets

Current Company
-16.8%
Current Industry
2.9%
MTEM is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

MTEM Return on Capital Employed

Current Company
-30.35%
Current Industry
19.5%
MTEM has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MTEM vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
MTEM$57.31M$1.16M-$8.12M+33.96%-92.71%
NTBL$310.00k-$10.28M-$11.15M-11.93%N/A
BRTX$145.80k-$14.16M-$14.42M+5.61%N/A
CHRO$0.00-$6.86M-$7.38M-100.00%N/A
ASLN$12.00M-$39.41M-$44.22M+41.42%N/A
View Top Biotech Stocks

MTEM earnings dates

Next earnings date
May 13, 2024

Molecular Templates Earnings & Revenue FAQ

What were MTEM's earnings last quarter?

On Invalid Date, Molecular Templates (NASDAQ: MTEM) reported Q4 2023 earnings per share (EPS) of $0.81, up 86.2% year over year. Total Molecular Templates earnings for the quarter were -$3.95 million. In the same quarter last year, Molecular Templates's earnings per share (EPS) was $5.87.

If you're new to stock investing, here's how to buy Molecular Templates stock.

What was MTEM's earnings growth in the past year?

As of Q2 2024, Molecular Templates's earnings has grown -92.71% year over year. This is 144.79 percentage points lower than the US Biotechnology industry earnings growth rate of 52.08%. Molecular Templates's earnings in the past year totalled -$8.12 million.

What is MTEM's earnings date?

Molecular Templates's earnings date is Invalid Date. Add MTEM to your watchlist to be reminded of MTEM's next earnings announcement.

What was MTEM's revenue last quarter?

On Invalid Date, Molecular Templates (NASDAQ: MTEM) reported Q4 2023 revenue of $7.02 million up 168.71% year over year. In the same quarter last year, Molecular Templates's revenue was $2.61 million.

What was MTEM's revenue growth in the past year?

As of Q2 2024, Molecular Templates's revenue has grown 190.1% year over year. This is 41.7 percentage points higher than the US Biotechnology industry revenue growth rate of 148.4%. Molecular Templates's revenue in the past year totalled $57.31 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.